About: Convalescent plasma for patients with severe COVID-19: a matched cohort study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Convalescent plasma for patients with severe COVID-19: a matched cohort study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Convalescent plasma for patients with severe COVID-19: a matched cohort study
Creator	Ph, M Bailey, Jeffrey Eng, M Mylona, Evangelia Mylonakis, Eleftherios Shehadeh, Fadi Touzard-Romo, Francine Rich, Josiah Geffert, Sara Larkin, Jerome Lu, Shaolei Neill, Marguerite Rogers, Ralph Sweeney, Joseph
source	MedRxiv
abstract	Background The efficacy of convalescent plasma (CP) for the treatment of COVID-19 remains unclear. Methods A matched cohort analysis of hospitalized patients with severe COVID-19. The impact of CP treatment on all cause in-hospital mortality was evaluated using univariate and multivariate Cox proportional-hazards models, and the impact of CP treatment on the time to hospital discharge was assessed using a stratified log-rank analysis. Results 64 patients who received CP a median of 7 days after symptom onset were compared to a matched control group of 177 patients. Overall in-hospital mortality was 14.9%. There was no significant difference in the risk of in-hospital mortality between the two groups (adjusted hazard ratio [aHR] 0.93, 95% confidence interval [CI] 0.39 - 2.20). There was also no significant difference in the overall rate of hospital discharge (rate ratio [RR} 1.28, 95% CI 0.91 - 1.81), but a subgroup analysis of patients 65-years-old or greater who received CP demonstrated a significantly increased hospital discharge rate among these patients (RR 1.86, 95% CI 1.03 - 3.36). There was a greater than expected frequency of transfusion reactions in the CP group (2.8% reaction rate observed per unit transfused). Conclusions The use of CP in this study was a safe treatment for COVID-19. There was no overall significant reduction of in-hospital mortality or increased rate of hospital discharge associated with the use of CP in this study, although there was a signal for improved outcomes among the elderly. Further adequately powered randomized studies should target this subgroup when assessing the efficacy CP treatment.
has issue date	2020-08-21(xsd:dateTime)
bibo:doi	10.1101/2020.08.18.20177402
has license	medrxiv
sha1sum (hex)	39d72bd0fe3295fccb92f1a34498aea32ba4cfe4
schema:url	https://doi.org/10.1101/2020.08.18.20177402
resource representing a document's title	Convalescent plasma for patients with severe COVID-19: a matched cohort study
resource representing a document's body	covid:39d72bd0fe3295fccb92f1a34498aea32ba4cfe4#body_text
is schema:about of	named entity 'plasma' named entity 'cohort study' named entity 'cohort study' named entity 'COVID-19' named entity 'preprint' named entity 'antibody' named entity 'transfusion' named entity 'critically ill patients' named entity 'clinical outcomes' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'COVID-19' named entity 'hemodialysis' named entity 'peer review' named entity 'medRxiv' named entity 'clinical outcomes' named entity 'COVID' named entity 'electronic health record' named entity 'plasma' named entity 'COVID' named entity 'thrombosis' named entity 'preprint' named entity 'Stata' named entity 'reaction rate' named entity 'antibody' named entity 'pandemic influenza' named entity 'chest pain' named entity 'standard deviation' named entity 'antibodies' named entity 'copyright holder' named entity 'preprint' named entity 'transfusion reactions' named entity 'transfusion-related acute lung injury' named entity 'preprint' named entity 'convalescent plasma' named entity 'preprint' named entity 'clinical outcomes' named entity 'preprint' named entity 'expanded access' named entity 'preprint' named entity 'China' named entity 'medRxiv' named entity 'statistically significant' named entity 'invasive ventilation' named entity 'preprint' named entity 'transfusion' named entity 'titer' named entity 'preprint' named entity 'preprint' named entity 'transfusion reactions' named entity 'endothelium' named entity 'medRxiv' named entity 'local reaction' named entity 'plasma' named entity 'antibody titer' named entity 'interquartile range' named entity 'levels of evidence' named entity 'control group' named entity 'copyright holder' named entity 'preprint' named entity 'TRALI' named entity 'SARS-CoV-2' named entity 'copyright holder' named entity 'transfusion reaction' named entity 'clinical trials' named entity 'remdesivir' named entity 'medRxiv' named entity 'TRALI' named entity 'subgroup analysis' named entity 'placebo' named entity 'control group'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software